AGRENVEC S.L.

AGRENVEC S.L. is a private biotechnology company that produces high-quality recombinant proteins using plants as biofactories. Founded in 2002, and a pioneer in plant-based manufacturing, it has developed a broad portfolio of recombinant human proteins for skincare, diagnostics, research, and biotechnological applications. Its R&D and manufacturing headquarters are located in the Tres Cantos Technology Park. The expanded manufacturing capacity is already operational in its state-of-the-art facilities to produce hundreds of grams of recombinant protein each year.

• General Characteristics

  • ACTIVITY: Biotechnology: production of recombinant proteins in plants.
  • LOCATION: c/Santiago Grisolía, Technology Park, 28760 Tres Cantos, Madrid.
  • DATE OF ESTABLISHMENT: 05/11/2001.
  • CATEGORY: SME.
  • CONTACT: isabel.bronchalo@agrenvec.es / www.agrenvec.es

• Business Structure

  • NUMBER OF EMPLOYEES: 22.
  • REVENUE: 1.5 M€.
  • GENERAL DESCRIPTION: A private biotechnology company that produces high-quality recombinant proteins using plants as biofactories. Founded in 2002 and a pioneer in plant-based manufacturing, it has developed a broad portfolio of recombinant human proteins for skin care, diagnostics, research, and biotechnological applications. Its R&D and manufacturing headquarters are located in the Tres Cantos Technological Park. The expanded manufacturing capacity is already operational in its cutting-edge facilities to produce hundreds of grams of recombinant protein each year.
  • BUSINESS LINES:
    • Production of human proteins for the dermocosmetic market.
    • Production of proteins as reagents used in diagnostics.
    • Production of growth factors for cultured meat growth media.
  • INFRASTRUCTURE: laboratory 300 m2 and plant production facility 2,000 m2.

• R&D Activities/Interests

TECHNOLOGICAL OFFER/DEMAND:

  • Offer: production of custom recombinant proteins.
  • Demand: proteomics services, cell culture, expression systems in plants.

• Participation in projects

It has not requested public funding in the last eight years; all developments have been financed with own resources.